Systemic Juvenile Idiopathic Arthritis

3

Review clinical trials related to Systemic Juvenile Idiopathic Arthritis. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

Allogeneic Hematopoietic Cell Transplantation for Refractory Systemic Juvenile Idiopathic Arthritis.

The goal of this study is to collect clinical data and samples and to evaluate the feasibility of allogeneic hematopoietic cell transplantation (HCT) in children and young adults with refractory Systemic Juvenile Idiopathic Arthritis (sJIA), including those with sJIA-associated lung disease (sJIA-LD).

Participants needed: 20
Trial details
Age: Up to 35Biological sex: AllType: ObservationalSponsor: Children's Hospital Medical Center, CincinnatiUpdated: Sep 29, 2026Locations: 1
Eligibility criteria

Diagnosis: Systemic Juvenile Idiopathic Arthritis (sJIA) diagnosed prior to age... [+3]

Uncontrolled Infection: Presence of a severe, uncontrolled infection at time of... [+4]

Status: Not yet recruiting

Clinical Features and Treatment of Systemic JIA in Children

This study aims to describe the clinical features, disease patterns, and different treatment modalities used in children with systemic juvenile idiopathic arthritis (sJIA). The study will include children younger than 18 years who meet the established classification criteria for sJIA. Clinical findings, laboratory investigations, disease activity, complications, and treatments received will be assessed. Participants will be followed prospectively to evaluate their clinical course and response to different therapeutic approaches. The study will help improve understanding of sJIA in children and provide information about the outcomes associated with different treatment modalities.

Participants needed: 50
Trial details
Age: Up to 18Biological sex: AllType: ObservationalSponsor: Sohag UniversityUpdated: Sep 11, 2026Locations: 1Duration: 12 Months
Eligibility criteria

Children aged <18 years. [+2]

Children with other rheumatic or autoimmune diseases. [+2]

Status: Recruiting

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Participants needed: 160
Trial details
Age: 1+Biological sex: AllType: ObservationalSponsor: Novartis PharmaceuticalsUpdated: Jun 9, 2026Locations: 1
Eligibility criteria

Pediatric or adult patients who were prescribed canakinumab before October 2021... [+1]